Vaccinia DynPort Vaccine Company LLC - Treatment for Complications of Smallpox Vaccination

Vaccinia Immune Globulin Intravenous (VIGIV) is the first intravenous human plasma-derived product available to treat certain rare complications of smallpox vaccination.

Posted: February 2005

Related Articles:

Vaccinia (vaccinia immune globulin intravenous (human)) FDA Approval History

View comments

Hide
(web2)